Interaction of molecular alterations with immune response in melanoma

Robert A. Szczepaniak Sloane, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Xue Zhang, Alexandre Reuben, Jennifer A. Wargo

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42.

Original languageEnglish (US)
Pages (from-to)2130-2142
Number of pages13
JournalCancer
Volume123
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Melanoma
Immunotherapy
Therapeutics
Translational Medical Research
United States Food and Drug Administration
Biomarkers
Mutation
Survival
Neoplasms

Keywords

  • B-Raf proto-oncogene serine/threonine kinase (BRAF)
  • catenin-β 1 (CTNNB1)
  • combination therapy
  • guanosine-triphosphate guanyltransferase (GTPase)
  • immunotherapy
  • melanoma
  • neoantigen
  • neuroblastoma rat sarcoma viral oncogene homolog (NRAS)
  • personalized medicine
  • phosphatase and tensin homolog (PTEN)
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Szczepaniak Sloane, R. A., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017). Interaction of molecular alterations with immune response in melanoma. Cancer, 123, 2130-2142. https://doi.org/10.1002/cncr.30681

Interaction of molecular alterations with immune response in melanoma. / Szczepaniak Sloane, Robert A.; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M.; Zhang, Xue; Reuben, Alexandre; Wargo, Jennifer A.

In: Cancer, Vol. 123, 01.06.2017, p. 2130-2142.

Research output: Contribution to journalReview article

Szczepaniak Sloane, RA, Gopalakrishnan, V, Reddy, SM, Zhang, X, Reuben, A & Wargo, JA 2017, 'Interaction of molecular alterations with immune response in melanoma', Cancer, vol. 123, pp. 2130-2142. https://doi.org/10.1002/cncr.30681
Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 Jun 1;123:2130-2142. https://doi.org/10.1002/cncr.30681
Szczepaniak Sloane, Robert A. ; Gopalakrishnan, Vancheswaran ; Reddy, Sangeetha M. ; Zhang, Xue ; Reuben, Alexandre ; Wargo, Jennifer A. / Interaction of molecular alterations with immune response in melanoma. In: Cancer. 2017 ; Vol. 123. pp. 2130-2142.
@article{c84422c8818142ec92258dc802f9eb04,
title = "Interaction of molecular alterations with immune response in melanoma",
abstract = "Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42.",
keywords = "B-Raf proto-oncogene serine/threonine kinase (BRAF), catenin-β 1 (CTNNB1), combination therapy, guanosine-triphosphate guanyltransferase (GTPase), immunotherapy, melanoma, neoantigen, neuroblastoma rat sarcoma viral oncogene homolog (NRAS), personalized medicine, phosphatase and tensin homolog (PTEN), targeted therapy",
author = "{Szczepaniak Sloane}, {Robert A.} and Vancheswaran Gopalakrishnan and Reddy, {Sangeetha M.} and Xue Zhang and Alexandre Reuben and Wargo, {Jennifer A.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/cncr.30681",
language = "English (US)",
volume = "123",
pages = "2130--2142",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Interaction of molecular alterations with immune response in melanoma

AU - Szczepaniak Sloane, Robert A.

AU - Gopalakrishnan, Vancheswaran

AU - Reddy, Sangeetha M.

AU - Zhang, Xue

AU - Reuben, Alexandre

AU - Wargo, Jennifer A.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42.

AB - Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42.

KW - B-Raf proto-oncogene serine/threonine kinase (BRAF)

KW - catenin-β 1 (CTNNB1)

KW - combination therapy

KW - guanosine-triphosphate guanyltransferase (GTPase)

KW - immunotherapy

KW - melanoma

KW - neoantigen

KW - neuroblastoma rat sarcoma viral oncogene homolog (NRAS)

KW - personalized medicine

KW - phosphatase and tensin homolog (PTEN)

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85019916892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019916892&partnerID=8YFLogxK

U2 - 10.1002/cncr.30681

DO - 10.1002/cncr.30681

M3 - Review article

C2 - 28543700

AN - SCOPUS:85019916892

VL - 123

SP - 2130

EP - 2142

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -